Article citationsMore>>
Thuss-Patience, P.C., Shah, M.A., Ohtsu, A., Van Cutsem, E., Ajani, J.A., Castro, H., Mansoor, W., Chung, H.C., Bodoky, G., Shitara, K., Phillips, G.D.L., van der Horst, T., Harle-Yge, M.L., Althaus, B.L. and Kang, Y.-K. (2017) Trastuzumab Emtansine Versus Taxane Use for Previously Treated HER2-Positive Locally Advanced or Metastatic Gastric or Gastro-Oesophageal Junction Adenocarcinoma (GATSBY): An International Randomised, Open-Label, Adaptive, Phase 2/3 Study. The Lancet Oncology, 18, 640-653.
https://doi.org/10.1016/S1470-2045(17)30111-0
has been cited by the following article:
-
TITLE:
Antibody-Coupled Drugs in HER2-Positive Gastric Cancer
AUTHORS:
Baofeng Liu, Yuanmei Dai, Xiaohui Shen, Xiangyang Tian
KEYWORDS:
Antibody-Coupled Drugs, HER2-Positive Gastric Cancer, Review
JOURNAL NAME:
Journal of Biosciences and Medicines,
Vol.11 No.7,
July
7,
2023
ABSTRACT: Antibody drug conjugates (ADCs) are a new class of drugs that combine chemosynthetic drugs with antibody drugs through a linker. Antibody drug conjugates combine the targeting characteristics of traditional antibody drugs with the cytotoxic characteristics of small molecule drugs, while reducing the side effects of both drugs, making them a kind of “biological missile” and representing a relatively new and evolving class of anti-cancer drugs. Antibody-coupled drugs are currently used in many solid tumors, and this article reviews the clinical application of antibody-coupled drugs in HER2-positive gastric cancer.
Related Articles:
-
Francesca Gallivanone, Carla Canevari, Paola Mapelli, Maria Picchio, Luigi Gianolli, Maria Carla Gilardi, Isabella Castiglioni
-
Toru Matsumura, Yuichi Sato
-
Désiré Allassem, B. Mahamout Mahamat, Adoum Kriga, Yaya Dagal Dari, Mahamat Hassan Béchir, Mahamat Ahmat Taha, Yacoub Nassian Nimir, Jean Pierre Chatelon, Jean-Jacques Rousseau
-
Ali Al-Qahtani, Houari B. Khenous, Shaban Aly
-
Mingxi Chen, Chao Tang, Tadao Tanabe, Yutaka Oyama